CTI BioPharma Corp. said Phillip Nudelman and Jack Singer resigned as board members.

Their resignations are not due to any disagreement with the company's board or management.

Nudelman stepped down due to health reasons. Singer will remain at CTI BioPharma as executive vice president, chief scientific officer, interim chief medical officer and global head of translational medicine.

Additionally, the company appointed David Parkinson to its board, to serve until the next CTI BioPharma annual shareholder meeting. Parkinson is president and CEO of ESSA Pharma Inc.